Biogen Inc.
BIIBHealthcareNASDAQDrug Manufacturers - General · Last scanned Sep 9, 2026
Scan Results
Daily timeframePart of the healthcare sector, Biogen Inc. (BIIB) is listed under Drug Manufacturers - General. Valued at $31.40B, BIIB is a large-cap name in its sector. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE.
Market Cap
$31.40B
Beta
0.17
P/E (TTM)
37.74
P/E (Fwd)
12.84
EPS (TTM)
$5.63
EPS (Fwd)
$16.54
ROE
4.6%
ROA
5.2%
Cash
$1.28B
Total Debt
$8.36B
Free CF
$1.27B
52W Change
54.9%
Annual Financials
Cash vs Debt
Where BIIB stands vs its 150-day and 200-day moving averages
As of the August 7, 2026 close, BIIB finished 8.26% above its 150-day moving average ($190.54) and 11.75% above its 200-day moving average ($184.59). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is BIIB overbought or oversold?
At the August 7, 2026 close, BIIB's RSI(14) was 50.3, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $1.28B in cash, though total debt stands at $8.36B. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Free cash flow comes in at $1.27B, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of 4.6% points to modest capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 5.2% suggests reasonable efficiency in deploying the company's asset base. Revenue has been relatively flat, moving from $10.17B (2022) to $9.89B (2025).
With a beta below 0.7, Biogen Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. Biogen Inc. carries a heavier debt load relative to its cash position, which introduces financial risk that investors should weigh. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing BIIB.